Adlai Nortye Group Ltd.

Stage 2 · Advancing · week 10

As of Oct 22, 2026, Adlai Nortye Group is in Stage 2, the uptrend phase, now in week 10 (since Aug 13, 2026). It closed at $10.58, 36.3% below its 52-week high and below its 200-day average, which is rising.

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. More about the company

$10.58

-4.86% today

$681M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ANL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-09-29 → 2026-10-22

S? 42w

S4 19w

S2 22w

2023-09-292026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S4 19w → S1 9w → S4 6w → S1 5w → S4 19w → S1 9w → S4 11w → S1 1w → S2 22w → S3 6w → S2 10w current

Total tracked: 159 weeks across 12 stage runs.

ANL among Biotechnology9th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
9	ANLAdlai Nortye Group Ltd.	Stage 2 · wk 10	99	−32.8%

vs 52W High

-36.3%

$0.88 lo$16.60 hi

36.3% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 10

1w13w26w

Week 10, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-4.9%

200 DMA: $11.13 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.74x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-32.8%

-15.4%

-29.0%

YTD

+666.7%

+539.3%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S2

Wk 10 · Vol 0.74x

2026-10-21S2

Wk 10 · Vol 2.27x

2026-10-20S2

Wk 10 · Vol 1.10x

2026-10-19S2

Wk 10 · Vol 1.63x

2026-10-16S2

Wk 10 · Vol 1.54x

2026-10-15S2

Wk 9 · Vol 4.25x

2026-10-14S2

Wk 9 · Vol 1.90x

2026-10-13S2

Wk 9 · Vol 5.19x

2026-10-12S2

Wk 9 · Vol 2.33x

2026-10-09S2

Wk 9 · Vol 1.71x

2026-10-08S2

Wk 8 · Vol 6.24x

2026-10-07S2

Wk 8 · Vol 0.59x

Moving averages & range

50 DMA

$14.21

200 DMA

$11.13

52W High

$16.60

52W Low

$0.88

5D Low

$10.38

Resistance levels (recent highs)

20d High

$16.00

60d High

$16.60

120d High

$16.60

250d High

$16.60

Next resistance

+51.2%

to 20d High

ROE

-20.2%

Profit margin -124.8%

Dividend Yield

0.00%

P/B 3.2

Adlai Nortye Group: quick answers

What stage is Adlai Nortye Group in?

As of Oct 22, 2026, Adlai Nortye Group (ANL) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 13, 2026 and is in week 10. What the four stages mean

Is Adlai Nortye Group in an uptrend?

Yes. Adlai Nortye Group is in a Stage 2 uptrend. It trades 4.9% below its 200-day average, which is rising.

How far is Adlai Nortye Group from its 52-week high?

Adlai Nortye Group closed at $10.58 on Oct 22, 2026, 36.3% below its 52-week high of $16.60. Its 52-week low is $0.88.

How has Adlai Nortye Group performed over the past year?

As of Oct 22, 2026, Adlai Nortye Group is up 539.3% over the past year and up 666.7% so far in 2026.

Which sector and industry is Adlai Nortye Group in?

Adlai Nortye Group is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.